We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+8.91%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$785M
AUM Growth
+$300M
(+62%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
32.59%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
72
New
25
Increased
20
Reduced
11
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASRT
Assertio
ASRT
|
+$27M |
| 2 |
Energizer
ENR
|
+$19M |
| 3 |
PLYA
Playa Hotels & Resorts
PLYA
|
+$13.2M |
| 4 |
BBBY
Bed Bath & Beyond Inc
BBBY
|
+$12.7M |
| 5 |
GCI
Gannett Co., Inc
GCI
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KATE
Kate Spade & Company
KATE
|
+$13.3M |
| 2 |
Deckers Outdoor
DECK
|
+$10.8M |
| 3 |
VSTO
Vista Outdoor Inc.
VSTO
|
+$9.27M |
| 4 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$8.5M |
| 5 |
Boston Beer
SAM
|
+$7.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.65% |
| 2 | Consumer Discretionary | 21.97% |
| 3 | Consumer Staples | 11.32% |
| 4 | Industrials | 3.49% |
| 5 | Communication Services | 1.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Abercrombie & Fitch
ANF
$4.23B
| $11.2M | 1.43% |
900,000
+450,000
| +100% | +$5.54M |
|
|
BBBY
27
DELISTED
Bed Bath & Beyond Inc
BBBY
| $10.7M | 1.36% |
+352,000
| New | +$12.7M |
|
|
FTD
28
DELISTED
FTD Companies, Inc. Common Stock
FTD
| $10.6M | 1.35% |
528,000
+28,000
| +6% | +$539K |
|
|
RXDX
29
DELISTED
Ignyta, Inc.
RXDX
| $10.3M | 1.32% |
1,000,000
-486,000
| -33% | -$3.95M |
|
30
Dollar General
DG
$27.7B
| $10.1M | 1.29% |
+140,000
| New | +$10.1M |
|
31
Tyson Foods
TSN
$20.3B
| $10M | 1.28% |
+160,000
| New | +$9.81M |
|
|
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $9.73M | 1.24% |
820,000
-30,000
| -4% | -$373K |
|
|
AET
33
DELISTED
Aetna Inc
AET
| $9.72M | 1.24% |
64,000
+14,000
| +28% | +$1.98M |
|
34
El Pollo Loco
LOCO
$505M
| $9.7M | 1.24% |
700,000
+50,000
| +8% | +$666K |
|
35
Enanta Pharmaceuticals
ENTA
$400M
| $9.5M | 1.21% |
264,000
-8,000
| -3% | -$256K |
|
|
SGYP
36
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $8.9M | 1.13% |
2,000,000
-250,000
| -11% | -$1.03M |
|
|
JCP
37
DELISTED
J.C. Penney Company, Inc.
JCP
| $8.37M | 1.07% |
+1,800,000
| New | +$9.2M |
|
|
ALIM
38
DELISTED
Alimera Sciences
ALIM
| $8.2M | 1.05% |
393,333
+97,600
| +33% | +$2.09M |
|
39
Carter's
CRI
$1.4B
| $6.94M | 0.88% |
+78,000
| New | +$6.86M |
|
|
PINC
40
DELISTED
Premier
PINC
| $6.55M | 0.84% |
+182,000
| New | +$6.22M |
|
|
41
CALL
Abercrombie & Fitch
ANF
$4.23B
| $6.22M | 0.79% |
+500,000
| New | +$6.16M |
|
|
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.14M | 0.78% |
+2,400,000
| New | +$6.54M |
|
|
NTRI
43
DELISTED
NutriSystem, Inc.
NTRI
| $5.21M | 0.66% |
+100,000
| New | +$5.18M |
|
44
Madrigal Pharmaceuticals
MDGL
$12.8B
| $4.58M | 0.58% |
282,000
+154,000
| +120% | +$2.41M |
|
45
BJ's Restaurants
BJRI
$1.42B
| $4.02M | 0.51% |
+108,000
| New | +$4.58M |
|
|
AVEO
46
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $3.55M | 0.45% |
160,000
-320,000
| -67% | -$2.52M |
|
47
Burlington
BURL
$21.7B
| $3.31M | 0.42% |
+36,000
| New | +$3.46M |
|
|
SFS
48
DELISTED
Smart & Final Stores, Inc.
SFS
| $3.31M | 0.42% |
+364,000
| New | +$4.35M |
|
|
BBBY
49
Bed Bath & Beyond
BBBY
$479M
| $3M | 0.38% |
+244,904
| New | +$2.94M |
|
|
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
| $2.96M | 0.38% |
+36,000
| New | +$2.7M |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Armistice Capital held 72 positions worth $785M, up 62% from $484M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Armistice Capital deployed $256M of net new capital in Q2 2017, opening 25 new positions and adding to 20 existing holdings. Its largest new stake was Assertio: 40,533 shares worth $26.1M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 37% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Antares Pharma, Inc., an estimated $8.5M trimmed.
- Armistice Capital's largest Q2 2017 buy was Assertio: 40,533 shares worth $26.1M.
- Armistice Capital added most to Hain Celestial in Q2 2017, an estimated $9.54M increase.
- Armistice Capital's biggest Q2 2017 reduction was Antares Pharma, Inc., cutting an estimated $8.5M.
- Armistice Capital fully exited Kate Spade & Company in Q2 2017, selling an estimated $13.3M.
- Armistice Capital's ten largest holdings make up 46% of its $785M portfolio in Q2 2017.
- Armistice Capital opened 25 new positions and closed 13 in Q2 2017.
- Armistice Capital's portfolio value rose 62% quarter-over-quarter to $785M.
Based on Armistice Capital's 13F filing for Q2 2017, filed 14 Aug 2017.